• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees.

作者信息

Gong Xiaohua, Yang Liuqing, Li Jie, Zhang Jiaqi, Wei Lanlan, Ye Guoguo, Tang Yimin, Jiang Yujing, Li Jianhuan, Lin Yuanlong, Wang Fuxiang, Lu Hongzhou, Liu Yingxia

机构信息

Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.

Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.

出版信息

J Infect. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2022.01.004. Epub 2022 Jan 10.

DOI:10.1016/j.jinf.2022.01.004
PMID:35016900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8743793/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c28f/8743793/0a2f43672c04/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c28f/8743793/6f2032cbbef7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c28f/8743793/0a2f43672c04/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c28f/8743793/6f2032cbbef7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c28f/8743793/0a2f43672c04/gr2_lrg.jpg

相似文献

1
Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees.使用灭活疫苗进行常规和加强接种可增强突破性感染患者和接种疫苗者对奥密克戎变种的中和活性。
J Infect. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2022.01.004. Epub 2022 Jan 10.
2
Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination.初次接种Covishield疫苗者对奥密克戎的中和抗体反应降低，这凸显了加强接种的重要性。
J Infect. 2022 Jul;85(1):90-122. doi: 10.1016/j.jinf.2022.04.031. Epub 2022 Apr 21.
3
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people.老年人接种灭活病毒BBIBP-CorV疫苗后的异源加强免疫反应。
Lancet Infect Dis. 2022 Aug;22(8):1118-1119. doi: 10.1016/S1473-3099(22)00427-3. Epub 2022 Jun 28.
4
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.mRNA 加强免疫可引发针对 SARS-CoV-2 奥密克戎变异株的强效中和血清活性。
Nat Med. 2022 Mar;28(3):477-480. doi: 10.1038/s41591-021-01676-0. Epub 2022 Jan 19.
5
Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.一项为期15个月的随访研究中灭活疫苗加强针（科兴新冠疫苗）对奥密克戎变异株的抗体效力
J Infect. 2022 Oct;85(4):e119-e121. doi: 10.1016/j.jinf.2022.06.018. Epub 2022 Jun 26.
6
Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections.加强针接种后抗体反应较弱的个体更容易感染奥密克戎突破性感染。
Front Immunol. 2022 Jun 23;13:907343. doi: 10.3389/fimmu.2022.907343. eCollection 2022.
7
Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.使用日本脑炎灭活疫苗加强免疫六年后抗体的持续性。
Vaccine. 2015 Jul 9;33(30):3600-4. doi: 10.1016/j.vaccine.2015.05.037. Epub 2015 May 30.
8
Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.初免一剂vero 细胞培养灭活流行性乙型脑炎疫苗（JE-VC）后的长期免疫原性，以及既往接种过鼠脑源灭活流行性乙型脑炎疫苗儿童再次接种JE-VC 疫苗的安全性和免疫原性。
Vaccine. 2018 Mar 7;36(11):1398-1404. doi: 10.1016/j.vaccine.2018.01.075.
9
Effect of Booster Vaccination with Inactivated Porcine Epidemic Diarrhea Virus on Neutralizing Antibody Response in Mammary Secretions.灭活猪流行性腹泻病毒加强免疫对乳腺分泌物中中和抗体反应的影响。
Viral Immunol. 2018 Jan/Feb;31(1):62-68. doi: 10.1089/vim.2017.0023. Epub 2017 Aug 7.
10
Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.牛和羊在加强免疫两种商品化的蓝舌病病毒 8 型灭活疫苗后中和抗体应答。
Vet J. 2011 May;188(2):193-6. doi: 10.1016/j.tvjl.2010.04.001. Epub 2010 May 13.

引用本文的文献

1
Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China.疫苗接种、感染与混合免疫：中国衢州新冠病毒 IgG 抗体水平及保护作用的决定因素
Front Immunol. 2025 Jul 28;16:1576016. doi: 10.3389/fimmu.2025.1576016. eCollection 2025.
2
Clinical characteristics and prognostic factors of COVID-19 infection among cancer patients during the December 2022 - February 2023 Omicron variant outbreak.2022年12月至2023年2月奥密克戎变异株流行期间癌症患者中新型冠状病毒肺炎感染的临床特征及预后因素
Front Med (Lausanne). 2024 May 30;11:1401439. doi: 10.3389/fmed.2024.1401439. eCollection 2024.
3

本文引用的文献

1
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.对 COVID-19 康复者的抗体动态进行纵向分析显示，感染后长达 16 个月仍存在中和反应。
Nat Microbiol. 2022 Mar;7(3):423-433. doi: 10.1038/s41564-021-01051-2. Epub 2022 Feb 7.
2
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
3
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
Results of the Cologne Corona Surveillance (CoCoS) project- a cross-sectional study: survey data on risk factors of SARS-CoV-2 infection, and moderate-to-severe course in primarily immunized adults.
科隆冠状病毒监测（CoCoS）项目的结果-一项横断面研究：关于 SARS-CoV-2 感染风险因素以及主要免疫成年人中中度至重度病程的调查数据。
BMC Public Health. 2024 Feb 21;24(1):548. doi: 10.1186/s12889-024-17958-4.
4
Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study.第二剂加强疫苗接种对奥密克戎变异株突破性感染临床结局的影响：一项倾向评分匹配队列研究。
Heliyon. 2023 Dec 7;10(1):e23344. doi: 10.1016/j.heliyon.2023.e23344. eCollection 2024 Jan 15.
5
Interactive effect of booster vaccination and vitamin D status on antibody production of Omicron variant-infected adults: A real-world cohort study.加强针接种和维生素 D 状态对奥密克戎变异株感染成年人抗体产生的交互作用：一项真实世界队列研究。
Clin Respir J. 2023 Oct;17(10):1067-1076. doi: 10.1111/crj.13694. Epub 2023 Sep 7.
6
Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.奥密克戎变异株可逃避 2 年 COVID-19 恢复期患者对 SARS-CoV-2 的持续特异性抗体应答，而无论其是否接种疫苗。
Emerg Microbes Infect. 2023 Dec;12(1):2151381. doi: 10.1080/22221751.2022.2151381.
7
Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings.充分了解 COVID-19 疫苗在多种真实环境中的疗效特征及其相关因素。
Front Immunol. 2022 Oct 25;13:947602. doi: 10.3389/fimmu.2022.947602. eCollection 2022.
8
A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD.一种针对所有当前变异株（VOCs）和变异引入株（VOIs）的更广泛的中和抗体靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域（RBD）的独特表位。
Cell Discov. 2022 Aug 17;8(1):81. doi: 10.1038/s41421-022-00443-w.
9
Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.新型冠状病毒灭活疫苗诱导的中和抗体对真实新型冠状病毒及其病毒变异株的血清学调查。
J Med Virol. 2022 Dec;94(12):6065-6072. doi: 10.1002/jmv.28049. Epub 2022 Aug 15.
10
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.奥密克戎变异株 COVID-19 疫苗的体液和细胞免疫应答：系统评价。
Int J Biol Sci. 2022 Jul 11;18(12):4629-4641. doi: 10.7150/ijbs.73583. eCollection 2022.
BNT162b2 或科兴疫苗接种者血清对严重急性呼吸综合征冠状病毒 2 奥密克戎变异株的中和作用。
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826. doi: 10.1093/cid/ciab1041.
4
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.康复期和疫苗血清对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）Mu变异株的中和作用
N Engl J Med. 2021 Dec 16;385(25):2397-2399. doi: 10.1056/NEJMc2114706. Epub 2021 Nov 3.
5
Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers.严重急性呼吸综合征冠状病毒2型伽马变异株所致新型冠状病毒肺炎的临床特征：一项针对接种和未接种疫苗医护人员的前瞻性队列研究。
J Infect. 2022 Feb;84(2):248-288. doi: 10.1016/j.jinf.2021.09.005. Epub 2021 Sep 16.
6
The biological and clinical significance of emerging SARS-CoV-2 variants.新兴 SARS-CoV-2 变体的生物学和临床意义。
Nat Rev Genet. 2021 Dec;22(12):757-773. doi: 10.1038/s41576-021-00408-x. Epub 2021 Sep 17.
7
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.SARS-CoV-2 中和抗体的亲和力成熟赋予了对病毒逃逸突变的效力、广度和恢复能力。
Immunity. 2021 Aug 10;54(8):1853-1868.e7. doi: 10.1016/j.immuni.2021.07.008. Epub 2021 Jul 30.
8
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.接种疫苗者、康复者和感染 P.1 变异株者对 SARS-CoV-2 B.1.1.7 和 P.1 变异株的交叉中和作用。
J Infect. 2021 Oct;83(4):467-472. doi: 10.1016/j.jinf.2021.07.019. Epub 2021 Jul 25.
9
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.感染 SARS-CoV-2 一年后自然增强的对其的中和广度。
Nature. 2021 Jul;595(7867):426-431. doi: 10.1038/s41586-021-03696-9. Epub 2021 Jun 14.
10
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.SARS-CoV-2 记忆 B 细胞反应的成熟和持久性。
Cell. 2021 Mar 4;184(5):1201-1213.e14. doi: 10.1016/j.cell.2021.01.050. Epub 2021 Feb 2.